Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05280158 · ClinicalTrials.gov registry record · Phase 1
High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients
A Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT05280158 is a Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 19 participants.
The verdict
NCT05280158, a Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Lung transplant recipients have poor outcomes after COVID-19 infection with mortality. Due to the immunosuppression, they have had poor responses to SARS-CoV-2 vaccine and remain at high risk of poor outcomes. This is a Phase I/II clinical trial to evaluate the safety and immune response from a higher dose mRNA-1273 vaccine among lung transplant recipients who have already received three or four doses of the COVID-19 vaccine.
Interventions
- DRUG mRNA-1273 (Moderna COVID-19 vaccine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05280158
The ClinicalTrials.gov registry entry for NCT05280158 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mRNA-1273 (Moderna COVID-19 vaccine) is the first listed.
NCT05280158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05280158 about?
NCT05280158 is a clinical study titled "High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients". Lung transplant recipients have poor outcomes after COVID-19 infection with mortality. Due to the immunosuppression, they have had poor responses to SARS-CoV-2 vaccine and remain at high risk of poor outcomes. This is a Phase I/II clinical trial to evaluate the safety and immune response from a high...
What is the current status of trial NCT05280158?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-03-10. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT05280158?
The interventions under investigation include: mRNA-1273 (Moderna COVID-19 vaccine) (DRUG).
Who is sponsoring clinical trial NCT05280158?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.